

DRUG METABOLISM AND DISPOSITION

A Publication of the American Society for Pharmacology and Experimental Therapeutics

September 2022

Vol. 50, No. 9

CONTENTS

SPECIAL SECTION ON NEW ERA OF TRANSPORTER SCIENCE:

UNRAVELING THE FUNCTIONAL ROLE OF ORPHAN

TRANSPORTERS

Special Section on New Era of Transporter Science: Unraveling the Functional Role of Orphan Transporters—Editorial. Yurong Lai and Xiaobo Zhong **1190**

[S] Emerging Roles of the Human Solute Carrier 22 Family. *Sook Wah Yee and Kathleen M. Giacomini.* **1193**

Transporters in Regulatory Science: Notable Contributions from Dr. Giacomini in the Past Two Decades. *Lei Zhang, Qi Liu, Shiew-Mei Huang, and Robert Lionberger.* **1211**

Clinical Applications and the Roles of Transporters in Disposition, Tumor Targeting, and Tissue Toxicity of *meta*-Iodobenzylguanidine. *Antonio J. López Quiñones, Leticia Salvador Vieira, and Joanne Wang.* **1218**

Amino Acid Solute Carrier Transporters in Inflammation and Autoimmunity. *Linlin Sheng, Qi Luo, and Ligong Chen* **1228**

Transcriptional Regulation of Solute Carrier Drug Transporters. *Shiwei Zhou and Yan Shu* **1238**

Impact of Inflammation and Infection on the Expression of Amino Acid Transporters in the Placenta: A Minireview. *Eliza R. McColl, Milena Hurtarte, and Micheline Piquette-Miller.* **1251**

ARTICLES

[S] The rs35217482 (T755I) Single-Nucleotide Polymorphism in Aldehyde Oxidase-1 Attenuates Protein Dimer Formation and Reduces the Rates of Phthalazine Metabolism. *Hinata Ueda, Katsuya Narumi, Ayako Furugen, Yoshitaka Saito, and Masaki Kobayashi.* **1126**

[S] Is the Protein-Mediated Uptake of Drugs by Organic Anion Transporting Polypeptides a Real Phenomenon or an Artifact?. *Mengyue Yin, Flavia Storelli, and Jashvant D. Unadkat.* **1132**

[S] Antibiotics-Induced Disruption of Gut Microbiota Increases Systemic Exposure of Clopidogrel Active Metabolite in Type 2 Diabetic Rats. *Xue Chen, Yingrui Liu, Hongwei Yao, Wenfang Song, Yu Song, Jingkai Gu, and Yingjie Gu* **1142**

The COVID-19 Oral Drug Molnupiravir Is a CES2 Substrate: Potential Drug-Drug Interactions and Impact of CES2 Genetic Polymorphism In Vitro. *Yue Shen, William Eades, William Liu, and Bingfang Yan.* **1151**

[S] Physiologically Based Pharmacokinetic Modeling of Vitamin D₃ and Metabolites in Vitamin D–Insufficient Patients. *Colton W. Sawyer, Stacey M. Tuey, Raymond E. West III, Thomas D. Nolin, and Melanie S. Joy.* **1161**

Physiologically Based Pharmacokinetic Models Can Be Used to Predict the Unique Nonlinear Absorption Profiles of Vismodegib. *Louis Lin, Matthew R. Wright, Cornelis E.C.A. Hop, and Harvey Wong.* **1170**

[S] High-Throughput Production of Diverse Xenobiotic Metabolites with Cytochrome P450–Transduced Huh7 Hepatoma Cell Lines. *Choon-myung Lee, Ken H. Liu, Grant Singer, Gary W. Miller, Shuzhao Li, Dean P. Jones, and Edward T. Morgan* **1182**

[S] Defining the Selectivity of Chemical Inhibitors Used for Cytochrome P450 Reaction Phenotyping: Overcoming Selectivity Limitations with a Six-Parameter Inhibition Curve-Fitting Approach. *Angela C. Doran, Woodrow Burchett, Connor Landers, Gabrielle M. Gualtieri, Amanda Balesano, Heather Eng, Alyssa L. Dantonio, Theunis C. Goosen, and R. Scott Obach.* **1259**

[S] An Improved Method for Cytochrome P450 Reaction Phenotyping Using a Sequential Qualitative-Then-Quantitative Approach. *Angela C. Doran, Alyssa L. Dantonio, Gabrielle M. Gualtieri, Amanda Balesano, Connor Landers, Woodrow Burchett, Theunis C. Goosen, and R. Scott Obach.* **1272**

- [S] Pharmacokinetic Modeling of Warfarin I – Model-Based Analysis of Warfarin Enantiomers with a Target Mediated Drug Disposition Model Reveals CYP2C9 Genotype-Dependent Drug-Drug Interactions of S-Warfarin. *Shen Cheng, Darcy R. Flora, Allan E. Rettie, Richard C. Brundage, and Timothy S. Tracy* **1287**
- [S] Pharmacokinetic Modeling of Warfarin II – Model-Based Analysis of Warfarin Metabolites after Warfarin Administered Either Alone or Together with Fluconazole or Rifampin. *Shen Cheng, Darcy R. Flora, Allan E. Rettie, Richard C. Brundage, and Timothy S. Tracy* **1302**
- [S] Transporter-Enzyme Interplay in the Pharmacokinetics of PF-06835919, a First-In-Class Ketoheokinase Inhibitor for Metabolic Disorders and Nonalcoholic Fatty Liver Disease. *Yan Weng, Kari R. Fonseca, Yi-an Bi, Sumathy Mathialagan, Keith Riccardi, Elaine Tseng, Andrew J. Bessire, Mathew A. Cerny, David A. Tess, A. David Rodrigues, Amit S. Kalgutkar, John Litchfield, Li Di, and Manthena V. S. Varma* **1312**

[S] Supplemental material is available online at <http://dmd.aspetjournals.org>.

About the cover: Timeline showing main key discoveries and events in research on the SLC22 family. See the article by Yee and Giacomini. ([dx.doi.org/10.1124/dmd.121.000702](https://doi.org/10.1124/dmd.121.000702)).